Bespoke ExtractsBSPK 10 Return-on-Tangible-Equity is 0.00% as of Sep. 2025. GuruFocus rates BSPK with a GF Score™ of 10/100 and a GF Value™ of $0.21 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 898 Drug Manufacturers companies, Bespoke Extracts ranks worse than 111358.46% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Bespoke Extracts's annualized net income for the quarter that ended in Sep. 2025 was $-0.31 Mil. Bespoke Extracts's average shareholder tangible equity for the quarter that ended in Sep. 2025 was $-2.58 Mil. Therefore, Bespoke Extracts's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2025 was N/A%.
The historical rank and industry rank for Bespoke Extracts's Return-on-Tangible-Equity or its related term are showing as below:
BSPK's Return-on-Tangible-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.88 * Ranked among companies with meaningful Return-on-Tangible-Equity only.
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Bespoke Extracts Return-on-Tangible-Equity Related Terms
Bespoke Extracts Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Bespoke Extracts's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSPK vs IMCC, NPHC, SKYI: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Bespoke Extracts's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bespoke Extracts Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bespoke Extracts's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Bespoke Extracts's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Sep. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.00% mean?
Bespoke Extracts (BSPK) has a Return-on-Tangible-Equity of 0.00% as of Sep. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bespoke Extracts and its competitors. According to the industry distribution chart, Bespoke Extracts ranks #999999 out of 898 companies in the Drug Manufacturers industry.
Is Bespoke Extracts' Return-on-Tangible-Equity too high?
Bespoke Extracts' current Return-on-Tangible-Equity is 0.00%. Based on the distribution chart, Bespoke Extracts ranks #999999 out of 898 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Bespoke Extracts has a GF Score™ of 10/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bespoke Extracts' Return-on-Tangible-Equity compare to IMCC and NPHC?
According to the Drug Manufacturers industry distribution chart, Bespoke Extracts ranks #999999 out of 898 companies for Return-on-Tangible-Equity. This places Bespoke Extracts in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.88. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.88, based on 898 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bespoke Extracts and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bespoke Extracts's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bespoke Extracts stock overvalued right now?
Based on GuruFocus' analysis, Bespoke Extracts (BSPK) is currently considered Possible Value Trap. The stock's GF Value™ is $0.21, compared to a current price of $0.12 — trading 42.7% below its estimated fair value. The current Return-on-Tangible-Equity is 0.00%. Bespoke Extracts' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Bespoke Extracts (BSPK), the current Return-on-Tangible-Equity is 0.00% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bespoke Extracts (BSPK) Overvalued in 2026?
Based on GuruFocus' analysis, Bespoke Extracts stock appears to be undervalued.
The current stock price of $0.12 is trading 42.7% below its estimated GF Value™ of $0.21.
GuruFocus considers Bespoke Extracts to be Possible Value Trap.
Key valuation signals for BSPK:
Return-on-Tangible-Equity: 0.00%
GF Value™: $0.21 vs. price of $0.12 (42.7% below fair value)
No single metric tells the full story. See the BSPK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bespoke Extracts Inc is focused on selling its proprietary line of specially-formulated, quality, hemp-derived CBD products. The company owns, manufactures, and distributes a portfolio of cannabis consumer packaged goods brands including Fresh Joints, Doobskis, DutchBlunts, and Wee Joints, to licensed marijuana dispensaries across Colorado.
10GF Score
Get the complete analysis for BSPK
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSPK has been successfully added to your 
